These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 33753332)
1. Antimicrobial Resistance Conferred by OXA-48 β-Lactamases: Towards a Detailed Mechanistic Understanding. Hirvonen VHA; Spencer J; van der Kamp MW Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753332 [TBL] [Abstract][Full Text] [Related]
2. OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline. Boyd SE; Holmes A; Peck R; Livermore DM; Hope W Antimicrob Agents Chemother; 2022 Aug; 66(8):e0021622. PubMed ID: 35856662 [TBL] [Abstract][Full Text] [Related]
3. Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii. Vázquez-Ucha JC; Maneiro M; Martínez-Guitián M; Buynak J; Bethel CR; Bonomo RA; Bou G; Poza M; González-Bello C; Beceiro A Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807908 [TBL] [Abstract][Full Text] [Related]
4. Penicillin sulfone inhibitors of class D beta-lactamases. Drawz SM; Bethel CR; Doppalapudi VR; Sheri A; Pagadala SR; Hujer AM; Skalweit MJ; Anderson VE; Chen SG; Buynak JD; Bonomo RA Antimicrob Agents Chemother; 2010 Apr; 54(4):1414-24. PubMed ID: 20086146 [TBL] [Abstract][Full Text] [Related]
5. Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β-lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D). Romero E; Oueslati S; Benchekroun M; D'Hollander ACA; Ventre S; Vijayakumar K; Minard C; Exilie C; Tlili L; Retailleau P; Zavala A; Elisée E; Selwa E; Nguyen LA; Pruvost A; Naas T; Iorga BI; Dodd RH; Cariou K Eur J Med Chem; 2021 Jul; 219():113418. PubMed ID: 33862516 [TBL] [Abstract][Full Text] [Related]
6. Mechanistic Basis of OXA-48-like β-Lactamases' Hydrolysis of Carbapenems. Stojanoski V; Hu L; Sankaran B; Wang F; Tao P; Prasad BVV; Palzkill T ACS Infect Dis; 2021 Feb; 7(2):445-460. PubMed ID: 33492952 [TBL] [Abstract][Full Text] [Related]
7. Targeting Multidrug-Resistant Barnes MD; Kumar V; Bethel CR; Moussa SH; O'Donnell J; Rutter JD; Good CE; Hujer KM; Hujer AM; Marshall SH; Kreiswirth BN; Richter SS; Rather PN; Jacobs MR; Papp-Wallace KM; van den Akker F; Bonomo RA mBio; 2019 Mar; 10(2):. PubMed ID: 30862744 [TBL] [Abstract][Full Text] [Related]
8. An Extended Reservoir of Class-D Beta-Lactamases in Non-Clinical Bacterial Strains. Lupo V; Mercuri PS; Frère JM; Joris B; Galleni M; Baurain D; Kerff F Microbiol Spectr; 2022 Apr; 10(2):e0031522. PubMed ID: 35311582 [TBL] [Abstract][Full Text] [Related]
10. New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams. Vázquez-Ucha JC; Arca-Suárez J; Bou G; Beceiro A Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291334 [TBL] [Abstract][Full Text] [Related]
12. Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity. Dortet L; Oueslati S; Jeannot K; Tandé D; Naas T; Nordmann P Antimicrob Agents Chemother; 2015 Jul; 59(7):3823-8. PubMed ID: 25870062 [TBL] [Abstract][Full Text] [Related]
13. Designing Inhibitors of β-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria. Davies DT; Everett M Acc Chem Res; 2021 May; 54(9):2055-2064. PubMed ID: 33788541 [TBL] [Abstract][Full Text] [Related]
14. Structural and Biochemical Features of OXA-517: a Carbapenem and Expanded-Spectrum Cephalosporin Hydrolyzing OXA-48 Variant. Dabos L; Raczynska JE; Bogaerts P; Zavala A; Girlich D; Bonnin RA; Dortet L; Peyrat A; Retailleau P; Iorga BI; Jaskólski M; Glupczynski Y; Naas T Antimicrob Agents Chemother; 2023 Feb; 67(2):e0109522. PubMed ID: 36648230 [TBL] [Abstract][Full Text] [Related]
15. A review on the mechanistic details of OXA enzymes of ESKAPE pathogens. Avci FG; Tastekil I; Jaisi A; Ozbek Sarica P; Sariyar Akbulut B Pathog Glob Health; 2023 May; 117(3):219-234. PubMed ID: 35758005 [TBL] [Abstract][Full Text] [Related]
16. Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamase. Werner JP; Mitchell JM; Taracila MA; Bonomo RA; Powers RA Protein Sci; 2017 Mar; 26(3):515-526. PubMed ID: 27997706 [TBL] [Abstract][Full Text] [Related]
17. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa. Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA mBio; 2018 Dec; 9(6):. PubMed ID: 30538183 [No Abstract] [Full Text] [Related]
18. OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Higgins PG; Pérez-Llarena FJ; Zander E; Fernández A; Bou G; Seifert H Antimicrob Agents Chemother; 2013 May; 57(5):2121-6. PubMed ID: 23439638 [TBL] [Abstract][Full Text] [Related]
19. Comparative Kinetic Analysis of OXA-438 with Related OXA-48-Type Carbapenem-Hydrolyzing Class D β-Lactamases. De Belder D; Ghiglione B; Pasteran F; de Mendieta JM; Corso A; Curto L; Di Bella A; Gutkind G; Gomez SA; Power P ACS Infect Dis; 2020 Nov; 6(11):3026-3033. PubMed ID: 32970406 [TBL] [Abstract][Full Text] [Related]
20. Comparative activity of beta-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA beta-lactamases. Bert F; Branger C; Lambert-Zechovsky N Chemotherapy; 2004 Apr; 50(1):31-4. PubMed ID: 15084803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]